Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

NCT06179303 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Locally Advanced Unresectable HER2-Negative Breast Carcinoma
Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma

Interventions

DRUG: Abemaciclib
DRUG: Anastrozole
PROCEDURE: Biospecimen Collection
PROCEDURE: Computed Tomography
PROCEDURE: Diagnostic Imaging Testing
DRUG: Exemestane
OTHER: Fludeoxyglucose F-18
DRUG: Fluorine F 18 Fluoro Furanyl Norprogesterone
DRUG: Fulvestrant
BIOLOGICAL: Gonadotropin-releasing Hormone Analog
DRUG: Letrozole
PROCEDURE: Positron Emission Tomography
DRUG: Tamoxifen
DRUG: Therapeutic Estradiol

Sponsor

University of Washington

Collaborators

Breast Cancer Research Foundation